KYMR Price Prediction Next Week
Analysis and Insights
To predict the stock price of Kymera Therapeutics (KYMR) for the next trading week, we analyze both technical indicators and recent news sentiment.
Technical Analysis:
Price Trends: KYMR is currently trading at $34.52, with a one-year high of $53.27 and a low of $29.24. The stock has shown volatility, with an average trading volume of 483.7K shares.
Technical Indicators:
- RSI (14): 48.14, indicating the stock is not in oversold territory.
- MACD: The MACD line (-1.19) is below the signal line (0.43), suggesting a bearish trend.
- Fibonacci Levels: The stock is trading near the Fibonacci pivot point of $32.43, with resistance at $34.89 and support at $29.97.
News Sentiment and Analyst Ratings:
Analyst Ratings: Multiple analysts have maintained a Buy rating on KYMR, with target prices ranging from $51.00 to $60.38. However, BMO Capital holds a Hold rating, indicating mixed sentiment.
Insider Activity: Recent insider selling activity, including a notable sale by CMO Jared Gollob, suggests negative sentiment among corporate insiders.
Options Market Insights:
- Put Contract: The $35.00 put contract has a 73% chance of expiring worthless, offering a 7.14% return on cash commitment.
- Call Contract: The $45.00 call contract has a 45% chance of expiring worthless, with a potential 20.03% return if exercised.
Prediction and Recommendation:
Based on the analysis, KYMR is expected to trade around $34.50 next week. The stock faces resistance at $34.89, and the options market suggests a higher probability of the stock staying below $35.00. Considering the mixed analyst sentiment and negative insider activity, it may be prudent to sell or wait for a clearer bullish signal before re-entering.
KYMR Similar Chart Price Prediction
The price of KYMR is predicted to go up -18.17%, based on the high correlation periods with BHAT. The similarity of these two price pattern on the periods is 96.26%.
KYMR
BHAT
Down: -18.17%Similarity: 96.26%
KYMR Revenue Forecast
KYMR EPS Forecast
KYMR FAQs
What is KYMR revenue forecast for next quarter？
What is KYMR eps forecast for next quarter？
KYMR Analyst's Forecast
Geoff Meacham
Citigroup
Strong Buy
2025-03-13
Price Target
$52
Upside
+55.46%
Citi initiated coverage of Kymera Therapeutics with a Buy rating and $52 price target. Healthcare policy remains a key biopharma sector uncertainty but major economic worries have underscored the defensive attributes of biotech, the analyst tells investors in a research note. The firm says that despite near-term "choppiness," a "barbell approach" to the sector still makes sense with higher-growth large caps likely able to absorb potential policy headwinds and catalyst-driven small-cap biotechs being insulated from macro uncertainties. Citi's preferred smaller caps are focused on unmet medical needs, have differentiated research and development platforms or are "clean growth stories." The firm highlights Apogee, Avidity, and Kymera as favorites.
Faisal Khurshid
Leerink Partners
Buy
2024-12-27
Price Target
$60
Upside
+49.59%
Jeet Mukherjee
BTIG
Strong Buy
2024-12-10
Price Target
$60
Upside
+33.19%
